

ONCOLOGY 101

Understanding the Value of YOUR Cancer Registry

Toni Hare, RHIT, CTR
Vice President, CHAMPS Oncology



OBJECTIVES



CANCER REGISTRARS

Understand the role and responsibilities of your cancer registrars and the impact they can have on your cancer program.



REGISTRY OPERATIONS


Recognize operational functions of your cancer registry, including casefinding, abstracting, follow-up and more.



CANCER REGISTRY DATA

Understand the importance and value of your cancer registry data to support your cancer program's care initiatives.

THE EVOLUTION OF CANCER REGISTRY DATA



WHAT IS THE CANCER REGISTRY?

Information system designed for the collection, management and analysis of data on persons with a cancer diagnosis.



3 TYPES OF CANCER REGISTRIES

HOSPITAL-BASED REGISTRY

Maintain data on all patients diagnosed and/or treated for cancer at their facility.


CENTRAL OR POPULATION-BASED REGISTRY

Maintain data on all cancer patients within certain geographical areas.

SPECIAL-PURPOSE REGISTRY

Maintain data on a particular type of cancer or tumors.

CANCER REGISTRY MILESTONES



WHO ARE THE STANDARD SETTERS?



NORTH AMERICAN
ASSOCIATION
CENTRAL CANCER
REGISTRIES
(NAACCR)



COMMISSION
ON CANCER
(COC)



NATIONAL PROGRAM
OF CANCER
REGISTRIES
(NPCR)



SURVEILLANCE,
EPIDEMIOLOGY &
END RESULTS
PROGRAM
(SEER)

STANDARD-SETTER ORGANIZATIONS

DATA FIELDS COLLECTED IN THE CANCER REGISTRY

| Patient ID | Cancer ID | Stage at Diagnosis | First Course of Treatment | |
|--------------------------|-----------------------------|-------------------------------|---------------------------------------|------------------------------------------------|
| Last Name | Date of Diagnosis | Regional Nodes Positive | Surgical Approach at RX Hospital | RX Summary – Treatment Status |
| First Name | Date of 1st Contact | Regional Nodes Examined | Surg Primary Site done at RX Hospital | Surgical Margins |
| Accession # | Primary Site | TNM Path T, N, M | Scope Regional LN Surgery Type | Reason for No Surgery |
| Sequence Number | Laterality | TNM Path Stage Group | RX Hospital – Surg Oth Reg/Dis | RX Summary – Radiation to CNS |
| Medical Record Number | Grade | TNM Path Descriptor | RX Hospital – Reg LN Removed | Sequence of Surgery and Radiation |
| Patient ID Number | DX Confirmation | TNM Path Staged By | RX Hospital – Surg Timing | Reason for No Radiation |
| Address at DX | Casefinding Source | TNM Clinical T, N, M | RX Hospital – Radiation | Reason for No Chemo |
| County at DX | Histologic Type ICD-O-3 | TNM Clinical Stage Group | RX Hospital – Chemo | Reason for No Hormone |
| Zip code at DX | Behavior Code ICD-O-3 | TNM Clinical Staged By | RX Hospital – Hormone | Radiation – Regional Dose: CGY |
| Marital Status at DX | Class of Case | Lymph - Vascular Invasion | RX Hospital – BRM | Radiation – # of Treatments |
| Race | DX Treatment | Tumor Size | RX Hospital – Other | Radiation – Treatment Site |
| Spanish/Hispanic Origin | Comorbidities/Complications | Extension | RX Hospital – DX/Sta Proc | Radiation – Facility of RX |
| Sex | | Lymph Nodes Status | Date of 1st Positive BX | RX Summary – Systemic Therapy/Surgery Sequence |
| Age at DX | | Mets at DX Status | Date and Type of Surgery | Physician – Managing |
| Date of Birth | | CS Site-Specific Factors 1-25 | Date and Type of Radiation | Physician – Follow-Up |
| Birthplace | | Pediatric Staging System | Date and Type of Chemo | Physician – Primary Surgeon |
| Text – Usual Occupation | | Pediatric Stage | Date and Type of Hormone | Treatment Text |
| Text – Usual Industry | | Pediatric Stage By | Date and Type of BRM | Readmission Same Hospital 30 Days |
| Tobacco History | | | Facility Referred To | Facility Referred From |
| Alcohol History | | | | |
| Family History of Cancer | | | | |
| Primary Payer at DX | | | | |



| Outcomes | Case Admin. |
|----------------------|--------------------|
| Date of Last Contact | Reporting Facility |
| Vital Status | Abstracted By |
| Cancer Status | |
| Recurrence Type | |

NEW DATA FIELDS COLLECTED FOR 2018

DATA ITEMS IN *STANDARDS for ONCOLOGY REGISTRY*

EMR:



New Sentinel and Regional Node Data Items



Radiation Treatment Revisions with New Data Items



New Follow-up Data Items

New Case Administration Data Item

See Appendix A of STORE Manual for List of Changes



WHY MAINTAIN THE CANCER REGISTRY?



IDENTIFY CANCER
INCIDENCE TRENDS



EVALUATE EFFECTIVENESS
OF TREATMENT



DETERMINE SURVIVAL
OUTCOMES



DEVELOP EDUCATION &
SCREENING PROGRAMS



CONDUCT CANCER STUDIES
ON EPIDEMIOLOGY, DX & TX

WHO UTILIZES CANCER REGISTRY DATA?



GOVERNMENT &
FEDERAL AGENCIES



HEALTHCARE
PROVIDERS



NATIONAL
ORGANIZATIONS

WHAT IS A CERTIFIED TUMOR REGISTRAR?

A CTR is a data information specialist that captures a complete history, diagnosis, treatment and health status on patients with a cancer diagnosis.



CANCER REGISTRY'S ROLE IN C oC ACCREDITATION

CoC-ACCREDITED CANCER PROGRAM VALUE

DEMONSTRATES an organizational model for the delivery of comprehensive, multidisciplinary cancer care.

REQUIRES participation in the National Cancer Database and provides access to numerous quality reporting tools.

PROVIDES data on patients treated within the facility to use for internal quality improvement, administration and research.

OPPORTUNITY for Participant User File participation in CoC special studies developed to address important issues in cancer care.

CoC DATA QUALITY REQUIREMENTS & STANDARDS

- ✓ CANCER REGISTRY POLICY & PROCEDURES (ER 5)
- ✓ CASEFINDING (ER 5)
- ✓ ABSTRACTING (ER 5)
- ✓ FOLLOW- UP (STANDARDS 5.3 & 5.4)
- ✓ CANCER REGISTRAR CREDENTIALS (STANDARD 5.1)
- ✓ RAPID QUALITY REPORTING SYSTEM (RQRS) PARTICIPATION (STANDARD 5.2)
- ✓ DATA SUBMISSION (STANDARD 5.5 & 5.6)
- COMMISSION ON CANCER SPECIAL STUDIES (STANDARD 5.7)

CoC STANDARDS THE CANCER REGISTRY SUPPORTS


-  CANCER COMMITTEE MEMBERSHIP (STANDARD 1.2)
-  QUALITY CONTROL OF REGISTRY DATA (STANDARD 1.7)
-  CANCER REGISTRY EDUCATION (STANDARD 1.11)
-  ACCOUNTABILITY MEASURES (STANDARD 4.4)
-  QUALITY IMPROVEMENT MEASURES (STANDARD 4.5)
-  STUDIES OF QUALITY (STANDARDS 4.7)
-  QUALITY IMPROVEMENTS (STANDARD 4.8)

THE VALUE OF THE CANCER REGISTRY DATA

WHAT IS CANCER DATA USED FOR?



ADMINISTRATIVE PLANNING & MARKETING



MIGRATION ANALYSIS



Migration Overview Timeline

3,030




3,964



Time Period Selected:


January 2016 to December 2016

Prior Services




Home Services
790

Post Services



POPULATION TRENDS & REFERRAL PATTERNS




SNAPSHOT OF MARKET SHARE REPORT

Total Market Share 20.87 %


| Primary Site | County | Newly Registered Patients (Analytic) † | State Totals* | Market Share |
|-----------------------|------------|----------------------------------------|---------------|--------------|
| + Bladder | Site Total | 68 | 408 | 16.67 % |
| + Brain | Site Total | 51 | 194 | 26.29 % |
| + Breast | Site Total | 475 | 1,512 | 31.42 % |
| + Cervix Uteri | Site Total | 17 | 64 | 26.56 % |
| + Colon | Site Total | 96 | 502 | 19.12 % |
| + Endocrine Benign | Site Total | 49 | 0 | N/A |
| + Endocrine Malignant | Site Total | 5 | 10 | 50.00 % |
| + Esophagus | Site Total | 13 | 67 | 19.40 % |
| + Eye and Orbit | Site Total | 10 | 23 | 43.48 % |
| + Hodgkin Lymphoma | Site Total | 9 | 67 | 13.43 % |

APPLYING FOR FUNDING & GRANTS



LINK CANCER REGISTRY DATA WITH FINANCIAL DATA

TO...



BREAST CANCER PERFORMANCE MEASURES

| PERFORMANCE MEASURES | BENCHMARK | REFERENCE | RESPONSIBILITY |
|-----------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------------|-----------------|
| Surgery: Mastectomy vs. breast conservation surgery rate - to ensure that women with stage 0-II BC are offered BCS | >50% | CoC CP ³ R measure NAPBC standard 2.3 | CANCER REGISTRY |
| Surgery: Needle biopsy vs open biopsy rate | >74.2% | CoC CP ³ R measure NAPBC standard 2.9 NQF #0221 | CANCER REGISTRY |
| Med Onc: combo chemo given within 120 days of dx for pt <70 with AJCC T1cN0M0, or stage II or III, ER/PR - (CP3R) | 100% | 100% for CoC CMS proposed reporting this quarterly NQF #0559 | CANCER REGISTRY |
| Med Onc: Tamoxifen or AI tx is initiated within 365 days of dx with AJCC T1cN0M0, or stage II or III, ER/PR + (CP3R) | 97% | 95% CoC NQF #0220 CMS has proposed reporting | CANCER REGISTRY |
| Rad Onc: Is Rad. Tx administered within 365 days of dx for <70 receiving BCT (C3PR) | 98% | 95% CoC NQF #0219 | CANCER REGISTRY |
| Surgery: Mastectomy vs. breast conservation surgery rate - ensure stage 0-II are offered BCT | >50% | NAPBC standard 2.3 | CANCER REGISTRY |

COC QUALITY REPORTING TOOLS



NATIONAL CANCER DATABASE (NCDB)

Nationwide oncology database w/34 million cancer cases.

Data on all cancers are tracked and analyzed.

Explore trends in care, use for treatment quality, create benchmarks.



HOSPITAL COMPARISON BENCHMARK REPORTS

Data reported to the NCDB from the cancer registry.

Aggregated data by hospital system, state, region or national level.

Cases submitted to NCDB by various programs.



CANCER PROGRAM PRACTICE PROFILE (CP³R)

Web-based quality reporting tool.

Identify problems in practice and delivery.

Assess adherence standard of care and implement best practices.

COG QUALITY REPORTING TOOLS



RAPID QUALITY REPORTING SYSTEM (RQRS)

Clinical tool to access real-time performance rates.
Alert clinical staff to prevent patients from experiencing delays.
Timely and accurate collection of treatment.



CANCER QUALITY IMPROVEMENT PROGRAM (CQIP)

Data-driven process and outcomes-based QI initiative.
Data includes: compliance with CoC-adopted quality measures, survival data, volume of complex surgeries and administrative data.



PARTICIPANT USER FILE (PUF)

Provide a researcher w/data to review and advance quality of care.
HIPAA-compliant data file containing cases submitted to CoC's NCDB.
Application only available to researchers in a CoC-accredited program.

BECOMING FAMILIAR WITH YOUR CANCER REGISTRY

OBTAIN COPY OF
STORE MANUAL

Patient / Cancer
Identification
Stage of Disease
First Course of Treatment
Outcomes

REVIEW REQUEST LOG
TO IDENTIFY

Data Requested
Date Request was Fulfilled
Intended Use of Data

PERFORM CANCER
REGISTRY ASSESSMENT

Operations
Workflow / Productivity
Quality of Data

CANCER REGISTRY RESOURCES

Standards for Oncology Registry Entry (STORE):

https://www.facs.org/~media/files/quality%20programs/cancer/ncdb/store_manual_2018.ashx

International Classification of Diseases for Oncology (ICD-O)

<http://codes.iarc.fr/>

Grade: <https://www.naaccr.org/SSDI/Grade-Manual.pdf>

SEER SITE/HISTOLOGY VALIDATION LIST <https://seer.cancer.gov/icd-o-3/>

Site-Specific Data Items (SSDIs): <https://apps.naaccr.org/ssdi/list/>

SEER HEMATOPOETIC & LYMPHOID NEOPLASM DATABASE:

<https://seer.cancer.gov/tools/heme/>

SEER*RX Interactive Drug Database: <https://seer.cancer.gov/seertools/seerrx/>

SUMMARY STAGING 2018: <https://seer.cancer.gov/tools/ssm/>

2018 SOLID TUMOR RULES: <https://seer.cancer.gov/tools/solidtumor/>

COC STANDARDS MANUAL (2016 EDITION)

https://www.facs.org/~media/files/quality%20programs/cancer/coc/2016%20coc%20standards%20manual_interactive%20pdf.ashx

STOP BY AND SEE US WITH ANY QUESTIONS



TONI HARE, RHIT, CTR



KAREN SCHMIDT, CTR



JOSEPH CASTELLANO